Biotie Buys Newron In Pain Deal; Price Brings Little Relief
Biotie's acquisition of pain-focused Newron for €38 million upfront reflects the trouble Newron was in - and the riskiness of the field.
Biotie's acquisition of pain-focused Newron for €38 million upfront reflects the trouble Newron was in - and the riskiness of the field.